Molecular Pathways in Cancers
This book includes some recent works providing the readers with novel relevant findings about the main signaling pathways that govern the molecular pathogenesis of some of the highest prevalent human tumors, which are the basis for developing alternative therapeutic strategies to improve patient out...
Enregistré dans:
| Autres auteurs: | , |
|---|---|
| Format: | Électronique Chapitre de livre |
| Langue: | anglais |
| Publié: |
Basel
MDPI - Multidisciplinary Digital Publishing Institute
2022
|
| Sujets: | |
| Accès en ligne: | DOAB: download the publication DOAB: description of the publication |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
MARC
| LEADER | 00000naaaa2200000uu 4500 | ||
|---|---|---|---|
| 001 | doab_20_500_12854_81202 | ||
| 005 | 20220506 | ||
| 003 | oapen | ||
| 006 | m o d | ||
| 007 | cr|mn|---annan | ||
| 008 | 20220506s2022 xx |||||o ||| 0|eng d | ||
| 020 | |a books978-3-0365-3681-1 | ||
| 020 | |a 9783036536828 | ||
| 020 | |a 9783036536811 | ||
| 040 | |a oapen |c oapen | ||
| 024 | 7 | |a 10.3390/books978-3-0365-3681-1 |c doi | |
| 041 | 0 | |a eng | |
| 042 | |a dc | ||
| 072 | 7 | |a M |2 bicssc | |
| 072 | 7 | |a MJCL |2 bicssc | |
| 100 | 1 | |a Cristóbal, Ion |4 edt | |
| 700 | 1 | |a Rodríguez, Marta |4 edt | |
| 700 | 1 | |a Cristóbal, Ion |4 oth | |
| 700 | 1 | |a Rodríguez, Marta |4 oth | |
| 245 | 1 | 0 | |a Molecular Pathways in Cancers |
| 260 | |a Basel |b MDPI - Multidisciplinary Digital Publishing Institute |c 2022 | ||
| 300 | |a 1 electronic resource (284 p.) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
| 520 | |a This book includes some recent works providing the readers with novel relevant findings about the main signaling pathways that govern the molecular pathogenesis of some of the highest prevalent human tumors, which are the basis for developing alternative therapeutic strategies to improve patient outcomes. | ||
| 540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |4 https://creativecommons.org/licenses/by/4.0/ | ||
| 546 | |a English | ||
| 650 | 7 | |a Medicine |2 bicssc | |
| 650 | 7 | |a Oncology |2 bicssc | |
| 653 | |a actin cytoskeletal reorganization | ||
| 653 | |a breast cancer | ||
| 653 | |a CD99 agonist | ||
| 653 | |a EGFR dimerization | ||
| 653 | |a endocytosis | ||
| 653 | |a FAK dephosphorylation | ||
| 653 | |a PTPN12 | ||
| 653 | |a Rac1 | ||
| 653 | |a RhoA | ||
| 653 | |a tripeptide | ||
| 653 | |a OMD | ||
| 653 | |a PRELP | ||
| 653 | |a tumor suppression gene | ||
| 653 | |a bladder cancer initiation | ||
| 653 | |a tight junction | ||
| 653 | |a partial EMT | ||
| 653 | |a tousled-like kinase (TLK) | ||
| 653 | |a NIMA-related kinase 1 (NEK1) | ||
| 653 | |a yes-associated protein 1 (YAP1) | ||
| 653 | |a thioridazine (THD) | ||
| 653 | |a MS-determined phosphopeptides | ||
| 653 | |a human immunodeficiency virus type 1 | ||
| 653 | |a epithelial cells | ||
| 653 | |a carcinogenicity | ||
| 653 | |a oxidative stress | ||
| 653 | |a reactive oxygen species | ||
| 653 | |a gp120 | ||
| 653 | |a Tat | ||
| 653 | |a Nef | ||
| 653 | |a matrix protein p17 | ||
| 653 | |a reverse transcriptase | ||
| 653 | |a mitochondria | ||
| 653 | |a metastasis | ||
| 653 | |a OXPHOS | ||
| 653 | |a cancer | ||
| 653 | |a Warburg effect | ||
| 653 | |a cancer therapeutics | ||
| 653 | |a myeloproliferative neoplasms | ||
| 653 | |a signaling pathways | ||
| 653 | |a JAK2 | ||
| 653 | |a CALR | ||
| 653 | |a MPL | ||
| 653 | |a TPOR | ||
| 653 | |a DUSP1 | ||
| 653 | |a MAPK | ||
| 653 | |a Snail | ||
| 653 | |a prostate cancer | ||
| 653 | |a migration and invasion | ||
| 653 | |a patient survival | ||
| 653 | |a biomarkers | ||
| 653 | |a pBRD4 | ||
| 653 | |a SET | ||
| 653 | |a PP2A | ||
| 653 | |a prognosis | ||
| 653 | |a triple negative breast cancer | ||
| 653 | |a resistance | ||
| 653 | |a anti-receptor therapy | ||
| 653 | |a trastuzumab | ||
| 653 | |a PI3K | ||
| 653 | |a mTOR | ||
| 653 | |a TAK-228 | ||
| 653 | |a epigenetic | ||
| 653 | |a methylation | ||
| 653 | |a acetylation | ||
| 653 | |a non-coding RNA | ||
| 653 | |a small-cell lung cancer | ||
| 653 | |a triple-negative breast cancer | ||
| 653 | |a pancreatic ductal adenocarcinoma | ||
| 653 | |a glioblastoma | ||
| 653 | |a metastatic melanoma | ||
| 653 | |a advanced ovarian cancer | ||
| 653 | |a hepatocellular carcinoma | ||
| 653 | |a immune evasion | ||
| 653 | |a immunotherapy | ||
| 653 | |a immune checkpoint inhibitors | ||
| 653 | |a oncogenic signaling pathway | ||
| 653 | |a molecular targeted agents | ||
| 653 | |a genome | ||
| 653 | |a epigenome | ||
| 653 | |a tumor immune microenvironment | ||
| 653 | |a ovarian cancer | ||
| 653 | |a adaptive immunity | ||
| 653 | |a innate immunity | ||
| 653 | |a complement system | ||
| 653 | |a cancer immunology | ||
| 653 | |a tumor microenvironment | ||
| 653 | |a splicing pathway | ||
| 653 | |a luminal breast cancer | ||
| 653 | |a BET inhibitors | ||
| 653 | |a n/a | ||
| 856 | 4 | 0 | |a www.oapen.org |u https://mdpi.com/books/pdfview/book/5234 |7 0 |z DOAB: download the publication |
| 856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/81202 |7 0 |z DOAB: description of the publication |